Table of Content

1. Introduction to Peptide Therapeutics
1.1 Overview of Peptide Therapeutics
1.2 Classification Of Anticancer Peptides
1.3 Designing & Functioning of Peptide Drugs
1.4 Significance of Peptides as Cancer Therapeutics
1.5 Role of Peptides in Cancer Immunotherapy


2. Global Cancer Peptide Therapeutics Market Insight
2.1 Current Market Scenario
2.2 Future Market Opportunities


3. Cancer Peptide Research & Market Trends by Country
3.1 US
3.2 China
3.3 Japan
3.4 South Korea
3.5 Australia
3.6 India
3.7 Canada
3.8 EU
3.9 Latin America
3.10 Middle East
3.11 UK


4. Cancer Peptide Research & Market Trends by Indication
4.1 Breast Cancer
4.2 Hematological Malignancies
4.3 Urothelial Cancer
4.4 Prostate Cancer
4.5 Lung Cancer
4.6 Gastrointestinal Cancer
4.7 Gynecological Cancer
4.8 Skin Cancer
4.9 Pancreatic Cancer
4.10 CNS Cancers


5. Marketed Cancer Peptides Drugs & Generics Insight – Availability, Cost, Dosage, Indication & Patent Insight
5.1 Firmagon (Degarelix)
5.1 Eligard (Leuprolide)
5.2 Lupron (Leuprolide Acetate)
5.3 Gonax (Degarelix Acetate)
5.4 Trelstar (Triptorelin)
5.5 Decapeptyl/Decapeptyl DR (Treptorelin Acetate or Pamoate)
5.6 Velcade (Bortizomib)
5.7 Ninlaro (Ixazomib)
5.8 Kyprolis (Carfilzomib)
5.9 Istodax (Romidepsin)
5.10 Zoladex (Goserelin)
5.11 Cosmegen (Dactinomycin)
5.12 Somatuline Depot (Lanreotide)
5.13 Sandostatin (Octreotide Acetate)
5.14 Bynfezia Pen (Octreotide)
5.15 Lutathera (Lutetium Lu 177 dotatate)
5.16 Mepact (Mifamurtide)
5.17 Netspot (Gallium Ga 68 dotatate)
5.18 Camcevi (Leuprolide)


6. Marketed Cancer Peptides Drugs Sales Insight
6.1 Kyprolis
6.2 Zoladex
6.3 Lutathera
6.4 Sandostatin
6.5 Somatuline
6.6 Decapeptyl SR
6.7 Velcade
6.8 Ninlaro
6.9 Lupron


7. Global Peptide Cancer Drugs Clinical Trials Insight By Company, Country, Indication & Phase
7.1 Research
7.2 Preclinical
7.3 Phase I
7.4 Phase I/II
7.5 Phase II
7.6 Phase II/III
7.7 Phase III
7.8 Preregistration
7.9 Registered


8. Marketed Peptide Cancer Drugs Clinical Insight By Company, Country and Indication


9. Global Peptide Cancer Drug Market Dynamics
9.1 Favorable Market Parameters
9.2 Commercialization Challenges


10. Therapeutic Peptide Targets
10.1 Signal Transduction Pathways
10.2 Cell Cycle Regulation
10.3 Cell Death Pathways
10.4 Tumor Suppressor Protein
10.5 Transcription Factors


11. Peptide Drugs v/s Conventional Cancer Therapeutics
11.1 Peptide v/s Chemotherapy
11.2 Peptide v/s Monoclonal Antibody
11.3 Peptide v/s Gene Therapy
11.4 Peptide v/s Immunotherapy


12. Different Approaches of Peptides in Cancer Therapeutics
12.1 Hormonal Peptides
12.2 Radionuclide Drug Carrier
12.3 Peptide Vaccines
12.4 Cytotoxic Drug Carrier
12.5 Anticancer Peptides
12.6 Other Anticancer Drugs Closely Related to Peptides


13. Neoantigen Vaccine: An Emerging Tumor Immunotherapy
13.1 Personalized Neoantigen Based Vaccine in Cancer
13.2 Clinical Progress & Future Prospects


14. Venom Peptides: New Era for Cancer Peptide Therapy
14.1 Relevance of Venom Based Peptide Therapeutics
14.2 Drug Development Trends & Future Growth Avenues of Venom Peptides


15. Competitive Landscape
15.1 3B Pharmaceuticals
15.2 AsclepiX Therapeutics
15.3 Bicycle Therapeutics
15.4 Biohaven Labs
15.5 BrightPath Biotherapeutics
15.6 Bristol-Myers Squibb
15.7 Edinburgh Molecular Imaging
15.8 Gnubiotics Sciences
15.9 IDP Pharma
15.10 Janux Therapeutics
15.11 Medikine
15.12 Modulation Therapeutics
15.13 Novartis
15.14 Parabilis Medicines
15.15 PeptiDream
15.16 Perspective Therapeutics
15.17 Pharm-Sintez
15.18 Roche
15.19 Sapience Therapeutics
15.20 Vigeo Therapeutics
 



List of Tables

Table 1-1: Source or Chemical Nature of Early Peptides

Table 5-1: Trelstar - Recommended Dose (mg/week)
Table 5-2: Velcade - Dosage Regimen for Patients with Previously Untreated Multiple Myeloma

Table 13-1: Neoantigen Vaccines in Clinical Trials

Table 14-1: Other Venom Peptides in Cancer Therapy